The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
B16 as a Mouse Model for Human Melanoma
Open accessAbstract
This unit details protocols for in vivo models of subcutaneous growth and pulmonary metastases of B16 melanoma. Therapeutic approaches include the use of B16.GM‐CSF and rVVmTRP‐1 to induce autoimmune vitiligo and tumor protection. The induction and use of gp100‐specific therapeutic cytotoxic T lymphocytes (CTL) are discussed. Methods are also included for CTL induction, isolation and testing, CTL maintenance, and adoptive transfer. Support protocols detail the testing of mouse sera for presence of MDA‐specific antibodies by immunoblotting and ELISA, respectively. Additional sections, including growing B16 melanoma, enumerating pulmonary metastases, and use of recombinant viruses for vaccination, are discussed together with safety concerns.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Centers for Disease Control and Prevention
(2007) · Encyclopedia of Measurement and Statistics · doi:10.4135/9781412952644.n74 · Cited by 6,444
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Current Protocols in Molecular Biology
Teplitz, R. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03420090114049 · Cited by 1,803
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · cited 2×
“GMCSF), particularly when administered together with anti-CTLA-4 antibody (Hung et al., 1998; van Elsas et al., 1999).”
BackgroundKawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., & Rosenberg, S. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.347 · Cited by 862
Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines
Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., & Slingluff, C. L. (1994) · Science · doi:10.1126/science.7513441 · Cited by 824
A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens
Rosenberg, S. A. (1999) · Immunity · doi:10.1016/s1074-7613(00)80028-x · Cited by 566
Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P. F., Sette, A., Appella, E., & Rosenberg, S. A. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.8.3961 · Cited by 540
Overwijk, W. W., Tsung, A., Irvine, K. R., Parkhurst, M. R., Goletz, T. J., Tsung, K., Carroll, M. W., Liu, C., Moss, B., Rosenberg, S. A., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.277 · Cited by 493
Self-citation
Cited by
Rogers, C., Erkes, D. A., Nardone, A., Aplin, A. E., Fernandes-Alnemri, T., & Alnemri, E. S. (2019) · Nature Communications · doi:10.1038/s41467-019-09397-2 · Cited by 826
Exploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 810
Zander, R., Schauder, D., Xin, G., Nguyen, C., Wu, X., Zajac, A., & Cui, W. (2019) · Immunity · doi:10.1016/j.immuni.2019.10.009 · Cited by 648
Harrell, M. I., Iritani, B. M., & Ruddell, A. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060761 · Cited by 388
Xu, F., Liu, J., Liu, D., Liu, B., Wang, M., Hu, Z., Du, X., Tang, L., & He, F. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2690 · Cited by 373
Jiang, Y., Krishnan, N., Zhou, J., Chekuri, S., Wei, X., Kroll, A. V., Yu, C. L., Duan, Y., Gao, W., Fang, R. H., et al. (2020) · Advanced Materials · doi:10.1002/adma.202001808 · Cited by 371
Sielaff, M., Kuharev, J., Bohn, T., Hahlbrock, J., Bopp, T., Tenzer, S., & Distler, U. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00433 · Cited by 317
Uribe-Herranz, M., Rafail, S., Beghi, S., Gil-de-Gómez, L., Verginadis, I., Bittinger, K., Pustylnikov, S., Pierini, S., Perales-Linares, R., Blair, I. A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124332 · Cited by 316
“Although an increase in the total number of T cells infiltrating the tumor in the vancomycin-alone group was observed, the OVA T cell–specific response was, unexpectedly, not improved in the same group, suggesting that in nontreated tumors, cross presentation may increase the recognition of other TAAs (49, 50).”
BackgroundDriving gene-engineered T cell immunotherapy of cancer
Johnson, L. A., & June, C. H. (2017) · Cell Research · doi:10.1038/cr.2016.154 · Cited by 268
Engineered skin bacteria induce antitumor T cell responses against melanoma
Chen, Y. E., Bousbaine, D., Veinbachs, A., Atabakhsh, K., Dimas, A., Yu, V. K., Zhao, A., Enright, N. J., Nagashima, K., Belkaid, Y., et al. (2023) · Science · doi:10.1126/science.abp9563 · Cited by 191
Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination
Persano, S., Guevara, M. L., Li, Z., Mai, J., Ferrari, M., Pompa, P. P., & Shen, H. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.02.019 · Cited by 187
VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread
Li, X., Padhan, N., Sjöström, E. O., Roche, F. P., Testini, C., Honkura, N., Sáinz-Jaspeado, M., Gordon, E., Bentley, K., Philippides, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms11017 · Cited by 149
Helix aspersa maxima mucus exhibits antimelanogenic and antitumoral effects against melanoma cells
Ellijimi, C., Ben Hammouda, M., Othman, H., Moslah, W., Jebali, J., Mabrouk, H. B., Morjen, M., Haoues, M., Luis, J., Marrakchi, N., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.020 · Cited by 69
NK cell receptor NKG2D sets activation threshold for the NCR1 receptor early in NK cell development
Jelenčić, V., Šestan, M., Kavazović, I., Lenartić, M., Marinović, S., Holmes, T. D., Prchal-Murphy, M., Lisnić, B., Sexl, V., Bryceson, Y. T., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0209-9 · Cited by 62
Guevara, M. L., Jilesen, Z., Stojdl, D., & Persano, S. (2019) · ACS Omega · doi:10.1021/acsomega.9b00489 · Cited by 58
Noncalcemic 20-hydroxyvitamin D3 inhibits human melanoma growth in in vitro and in vivo models
Skobowiat, C., Oak, A. S. W., Kim, T.-K., Yang, C. H., Pfeffer, L. M., Tuckey, R. C., & Slominski, A. T. (2017) · Oncotarget · doi:10.18632/oncotarget.14193 · Cited by 44
“Usually it takes 5 to 10 days to reach a volume of 1 mm3 with an injection of approximately 105 – 106 cells [64, 68].”
Background
Metadata
- Authors
- Overwijk, W. W., & Restifo, N. P.
- Venue
- Current Protocols in Immunology
- Publisher
- Wiley
- Published
- 2000-10
- Volume
- 39
- Issue
- 1
- Pages
- Unit 20.1-Unit 20.1
- ISSN
- 1934-3671 (ISSN-L)
- 1934-368X
- OpenAlex
- W2129585732
- Cited by
- 434
- References
- 47
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.